IFP Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

IFP Advisors’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-21	Closed	-$1.02K	–	3175
2019 Q3	$1K	Buy	+21	New	+$1.51K	﹤0.01%	2963
2019 Q1	–	Sell	-21	Closed	-$3K	–	3579
2018 Q4	$3K	Hold	21	–	–	﹤0.01%	3085
2018 Q3	$5K	Hold	21	–	–	﹤0.01%	3241
2018 Q2	$5K	Hold	21	–	–	﹤0.01%	3298
2018 Q1	$6K	Hold	21	–	–	﹤0.01%	3107
2017 Q4	$6K	Sell	21 -1	-5%	-$329	﹤0.01%	3154
2017 Q3	$8K	Sell	22 -470	-96%	-$167K	﹤0.01%	3181
2017 Q2	$179K	Buy	492 +471	+2,243%	+$141K	0.01%	1192
2017 Q1	$6K	Hold	21	–	–	﹤0.01%	3234
2016 Q4	$5K	Sell	21 -14	-40%	-$2.81K	﹤0.01%	3337
2016 Q3	$8K	Buy	35 +14	+67%	+$2.91K	﹤0.01%	3000
2016 Q2	$4K	Buy	+21	New	+$9.68K	﹤0.01%	3281

Other funds holding DMK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LFAS

Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IFP Advisors's DMK Position: Q4 2019 in Review

IFP Advisors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2019, closing a stake of 21 shares — an estimated $1.02K sold.

IFP Advisors first reported a position in DMK in Q2 2016 and held it in 12 quarters. The position peaked at $179K in Q2 2017. 38 funds tracked by Wall St. Rank hold DMK as of Q4 2019.

IFP Advisors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2019 after selling out during the quarter.
IFP Advisors sold 21 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2019, an estimated $1.02K.
IFP Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2016 and held it in 12 quarters.
IFP Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $179K in Q2 2017.
38 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2019.

Based on IFP Advisors's 13F filing for Q4 2019, filed 17 Jan 2020.